| Filed On | Filing |
|---|---|
| 01 Oct 2026 |
8-K: Other Events
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development |
| 29 Sep 2026 |
8-K: Other Events
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib |
| 16 Sep 2026 |
8-K: Other Events
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development |
| 14 Sep 2026 |
8-K: Other Events
TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathwa... |
| 14 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 01 Jul 2026 | 8-K: Submission of Matters to a Vote of Security Holders; Other Events |
| 22 Jun 2026 | 8-K: Other Events |
| 02 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 08 May 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 06 May 2026 | 8-K: Other Events |
| 28 Apr 2026 | 8-K: Other Events |
| 22 Apr 2026 | 8-K: Other Events |
| 01 Apr 2026 | 8-K: Results of Operations and Financial Condition |
| 09 Mar 2026 | 8-K: Other Events |
| 06 Mar 2026 | 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation |
| 19 Feb 2026 | 8-K: Other Events |
| 04 Feb 2026 | 8-K: Other Events |
| 29 Jan 2026 | 8-K: Entry into a Material Definitive Agreement |
| 23 Dec 2025 | 8-K: Unregistered Sales of Equity Securities |
| 08 Dec 2025 | 8-K: Departure/Election of Directors or Officers; Compensation |
Loading...
